Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
At this point in time I agree with you. All hands on deck to right the ship, starts with righting the ship! Focus efforts internally on management for some semblance of MANAGEMENT.
While reading this petition I came across the following names
http://www.change.org/p/petition-for-briggs-for-cancer-immunotherapy-for-all?utm_source=petition_update&utm_medium=email&utm_campaign=petition_update_email
Notable signatories from the medical world include Professor James P. Allison, Chair of Immunology at MD Anderson and leader of Stand Up to Cancer's dream team in immunology, fellow leader Professor Antoni Ribas at UCLA, and co-leader Professor Cassian Yee. And in Australia, Professor Dale Godfrey, Dr. Phil Darcy, and Professor Fabienne Mackay, Chair of Immunology at Monash University.
Just listed to identify more players in the game
I'm surprised that you did not highlight this part
An improvement in survival or disease-related symptoms has not yet been established.
Now explain to me how an FDA approval is not hyping the product when they clearly state "An improvement in survival or disease-related symptoms has not yet been established."
Yet if we, NWBO, discuss matters from an open label trial we are attacked as hyping snake oil!!!! It drives me to the brink of rage!
I started my journey here only thinking of capital gain. I have long since grown since my initial investment. I just received this from an email
https://www.change.org/p/the-managing-editor-of-time-magazine-put-briggs-s-beautiful-smiling-face-on-the-cover-of-time-to-begin-a-new-era-in-cancer
I signed the original petition months ago. It appears that he is starting another one. I would recommend considering signing it.
I actually agree with you, they should remain as independent from WaPo as possible. Now is the time to strike with positive data, if any. It would shed light on, or keep AF from attacking/misleading/fomenting. My hope is that there is meaningful follow up from WaPo/SEC/DOJ and not just a bunch of talk.
I just stumbled across this article
http://www.cnbc.com/id/102040769?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=102040769#.
Why was NWBO not involved in this? If we are attempting a 2 continent approach why was NWBO not there?
It is interesting to identify the ebb and flow of PR's. My observation has been that shortly after a LP PR is a selling opportunity and shortly after a AF PR is a buying opportunity
Yes you are correct, if you do not hold shares in a margin account your shares are not eligible for shorts to use. I have said before and I will say again, if anyone is uncertain how their holdings are held, contact your brokerage firm and confirm what their policy is pertaining to holding shares in a margin account and holding shares in a non margin account. I would suggest not allowing shorts access to your shares, but that is my opinion and not to be taken as advice.
Can anyone determine what the response rate and the durability of response is for DCVax-Direct with a comparison to Merck's figures? I am not certain what durability of response means in the context of the trials.
Furthermore
WHITEHOUSE STATION, N.J., Sept. 4, 2014 /PRNewswire/ -- Merck (MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab) at a dose of 2 mg/kg every three weeks for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. This indication is approved under accelerated approval based on tumor response rate and durability of response. An improvement in survival or disease-related symptoms has not yet been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.
It's good enough for FDA to approve Merck for something that does not have established improvement in survival or disease-related symptoms, but it's not good enough for NWBO. I am at a loss for words.
Just Read that Merck received approval for this,
Study Cohort Supporting the Accelerated FDA Approval of Single-Agent KEYTRUDA
The approval of KEYTRUDA was based on data from a multi-center, open-label, randomized, dose-comparative study cohort of the ongoing KEYNOTE-001 Phase 1b trial in patients with unresectable or metastatic melanoma and progression of disease. Key eligibility criteria included prior treatment with ipilimumab (two or more doses at 3 mg/kg or higher) and a BRAF or MEK inhibitor, if BRAF V600 mutation-positive; and disease progression within 24 weeks following the last dose of ipilimumab. Patients were randomized to receive 2 mg/kg (n=89) or 10 mg/kg (n=84) of KEYTRUDA every 3 weeks until unacceptable toxicity or disease progression that was symptomatic, was rapidly progressive, required urgent intervention, occurred with a decline in performance status, or was confirmed at 4 to 6 weeks with repeat imaging. The major efficacy outcome measures were confirmed overall response rate as assessed by blinded independent central review using Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and duration of response. Tumor response was assessed every 12 weeks.
I am amazed that we have not received similar Accelerated Approval. Is there anyone that can provide insight as to why they receive accelerated approval and we have not? Also thank you to those who tirelessly provide details and insight on this board.
TOB you forget to include the most recent claim by the head of the DMC specifically refuting Adam Feuerstein and his misrepresenting facts, or do you not read? He can win when he skews data and misrepresents the issue, but when faced with facts he ends up losing.
Great questions, I am going to send an email to the company as follow up. I would really like to hear the response/update as an owner/investor. If I receive a response I will follow up with any details.
Here is my post on AF's recent PR
Anyone who follows Adam, please read his press release pertaining to NWBO at ASCO from 6/2/14 for an apparent discrepancy in writing and quotes from what the lead Dr. of the trial (Dr. Vivek) said at ASCO and the more recent article Adam has published pertaining to comments made by Dr. Buzdar. There is a discrepancy against Adam, for anyone who cares to do their own due diligence. Don't take my word, read Adam's press releases.
Well written highwayman. Thank you for writing that email.
Fantastic! Well written response Pyr, thank you.
TOB if you made the choice to remove the sticky, then you have actually gained a shred of respect from me. If it was removed by other administrators, then I applaud whomever removed it. TOB to argue that the sticky is fair an impartial on its own is false.
Price down 10% premarket, story from AF. We do need a response/clarity from NWBO.
LOL!!!!!!!
I agree, we could use more of the Pyr effect!
AF shorts = adam feuerstein followers who "short" stocks under the assumption that the stock will fail and profit from the downward movement in the stock price.
LTT = long term thinker, he posts on ihub
AF = Adam feuerstein
Some here would argue that LTT is actually AF who is to cowardly to post as himself. Either way they both speak/write very negatively about NWBO. They use misleading information to skew the thoughts of others towards the negative, based on false or opinionated data. AF had a history of writing attack pieces every time NWBO had something positive to report. I suggest reading the press releases from NWBO's yahoo page, go back through all of them during the last few months and you will get the picture.
Correct! Now that we are above $7.50 the additional purchase becomes support, as anytime the price is above $7.50 the buyer will have an automatic profit! It's called arbitrage.
Please recall the PR from April 15 2014, regarding the single buyer and the multiple stock purchase options available. We may have an additional $17 million should they chose to buy more stock.
LTT you say to not fight the momentum, then how do you explain shorting NWBO when the momentum is clearly against you?
I agree, anyone who can write to any and every media outlet you can about this stock. I wrote to Fox to request a follow up piece from their November piece. I am going to write more tonight. Hooray for the patients receiving treatment.
Let's not forget that last private purchase agreement made at $6.60ish, that had a second option to purchase more shares at a price of $7.50. Ladies and Gentlemen if we pass that price we can avoid dilution a little longer.
LTT I thought you said we should not be enthusiastic about the prospects of NWBO? I am under the impression that you shorted the stock at $6.50, to bad you didn't buy at $6.50. If you had bought you would not be losing more money today. Hooray for NWBO, and their patients, one positive day at a time.
Reefrad, thank you. I vented on LTT/AF earlier (do you hear me LTT, otherwise known as AF). I cannot stand his constant misrepresentations presented as fact or contrarian, when they are really just opinions.
Why don't you tell the patients in this trial who are receiving treatment and witnessing the benefits to "Curb their enthusiasm"? I imagine the conversation would go something like this,
LTT: So patient X it appears that your terminal cancer diagnosis of a few weeks to live now requires and adjustment as the cancer has stopped. Don't get your hopes up though because everyone dies someday.
Patient X: Thanks LTT for the reminder to not get my hopes up, I think I am going to go for a walk today and temper my enthusiasm about how my cancer has stopped growing, and in some cases shrunk in size. What was I thinking? How could I be so foolish as to exhibit enthusiastic behavior? Ohh and by they way thank you for advising me to not invest in NWBO, what garbage.
I have been dogging him all day. I find it entertaining
I wrote an email to Fox
Hi Fox Representative,
I am writing to provide details of a promising story developing. The story is in relation to Northwest Biotherapeutics Inc., you actually aired a story on them last year. There is new data out today that would be very helpful for those suffering from cancer. I am writing to request/inform you that a follow up story would be helpful for those who are not aware of this progress this company is making in the fight against cancer. Thank you for your time.
My question relating to trial expansion is as follows: If they (sponsor) are blinded then what data are they using to even consider if the trial may require expansion? Is the consideration coming from the CRO, and are they advising management to expand or are they hinting that expansion may be required? Does this have to do with the 99 patient update on the clinical trials website? To consider expanding would require data or a suggestion/recommendation. She brought the expansion up last webcast, and to mention it again is to me an indication that it is a matter of time before it happens. I also understand that to expand the trial may increase the probability of success, albeit slower timeframe to completion. Pyr great article again today, thank you for all your efforts and clarity. I welcome all questions and criticism.
I second Flipper's question for the list to ask LG.
I would request that if you are able to inquire about how German negotiations for reimbursement are coming along?
Highway, thank you for the update.
Check out the spike in price after your article, well done Sir! Keep it up
Great article!
Last 6-8 minutes
Shiny! I am a simple man, I like simple things, like a shiny new website to blast the good news I hope is coming soon!